Table 4.

Efficacy studies in Takayasu arteritis including pediatric patients.

Agent	Dose	Treatment duration	Patients	Design	Outcome	Reference
Methotrexate + corticosteroids	10–25 mg/week	34 months*	18 patients (children included)	Open label, prospective	Remission 81%	(157)
CYC followed by MTX + corticosteroids	CYC 1.5–1.7 mg/kg/day, MTX 12.5 mg/m2/week	12 weeks followed by 12–18 months maintenance	6 children	Open label, retrospective	Remission 100%	(158)
Tocilizumab	8 mg/kg every 4 weeks	9.5 months*	4 children	Open label, retrospective	Remission 100%	(159)
Tocilizumab	162 mg SQ	12 months	30 adults, 6 children	RDBPC	Relapse in 44% TCZ, 61% placebo	(160)

CYC, cyclophosphamide; MTX, methotrexate; TCZ, tocilizumab; RDBPC, randomized, double-blind, placebo-controlled. *Median.